WISE Closes Oversubscribed Series D Financing Round of €30 Million, Welcoming ENEA Tech and Biomedical as Strategic New Investor

MILAN--(BUSINESS WIRE)--Jun 17, 2026--

WISE S.p.A., a pioneering medical device company specializing in advanced implantable electrodes for neuromonitoring, neuromodulation, and brain-computer interface (BCI), today announced the successful closing of an oversubscribed Series D financing round totaling €30 million. The round was joined by ENEA Tech and Biomedical, an Italian foundation dedicated to innovation and technology transfer in the biomedical sector, which enters WISE's investor base as a strategic partner. This final closing builds on the first closing of the round completed in June 2024, which included a venture debt facility from the European Investment Bank (EIB) supported by InvestEU, alongside an equity investment from new investor Wallaby S.p.A. — the family office of the Scagliarini family (GVS S.p.A.) — and existing financial partners New Frontier S.r.l., Eureka Venture SGR, and Indaco Ventures SGR.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615967453/en/

Accelerating the Heron® Lead to Clinical Adoption

The primary use of the proceeds is to advance the development and clinical adoption of the Heron® lead, WISE's flagship product for spinal cord stimulation (SCS). The Heron® lead is the first SCS lead designed to deliver targeted, directional stimulation through a minimally invasive percutaneous implant technique — uniquely combining the therapeutic precision of surgical paddle leads with the lower procedural burden of cylindrical leads. This dual advantage translates into higher energy efficiency, better anatomical coverage, improved neural signal sensing, and reduced lead migration, representing a significant step forward in the treatment of chronic pain.

Proceeds will fund the Heron® lead’s regulatory certification pathway and first-in-human study, while also driving the commercial scale-up of WISE's full electrode portfolio across target markets.

A Differentiated Platform for Next-Generation Neurotechnology

WISE's proprietary Supersonic Technology enables the production of implantable electrodes and BCI systems consisting of stretchable electronic circuits integrated into ultra-thin elastomeric foils. Compared to conventional rigid electrodes, WISE's devices deliver superior tissue conformability, softness, and adhesion — qualities that are critical to both safety and therapeutic efficacy in neuromonitoring and neurostimulation applications. These unique characteristics of WISE's technology also enable enhanced precision in neural signal acquisition and stimulation, positioning WISE at the forefront of next-generation neural interfacing.

Alongside the Heron® lead, the round will support expanded commercialization of the WISE Cortical Strip (WCS®), the first soft, stretchable electrode for intraoperative neurophysiological monitoring (IONM) during brain tumor and epilepsy surgeries. The WCS® holds CE mark under MDR — the first cortical strip for IONM to achieve this certification — as well as FDA clearance and is commercially available in Europe, USA, and Australia.

Strengthening WISE's Governance

The round's closing also brings the appointment of Laura Iris Ferro as Chairperson of the company and the addition of Giuseppe Corvino to the Board of Directors. Laura Iris Ferro is one of the most prominent leaders in Italian and European biotech: founder of Gentium, a Nasdaq-listed company acquired in 2014 by Jazz Pharmaceuticals in a transaction worth approximately USD 1 billion, she is today President and co-founder of Bio4Dreams and holds leadership and investment roles across numerous innovative companies in the Life Sciences sector.

“The oversubscription of this Series D round is a testament to the strength of what our team has built — in technology, in medical research, and in our relationships with clinicians and partners,” said Luca Ravagnan, Chief Executive Officer of WISE. “Welcoming ENEA Tech and Biomedical into our investor base strengthens our mission to bring genuinely transformative neurotechnology to patients worldwide. With the Heron® lead, we are targeting a multi-billion-euro market with a product that addresses a long-lasting unmet clinical need. This financing gives us the resources to complete the journey from bench to bedside.”

“WISE represents a compelling convergence of advanced materials science, neuroscience, and clinical innovation,” commented Laura Iris Ferro, Chairperson of WISE. “Welcoming ENEA Tech and Biomedical on board is a testament to the strength of what WISE has built. I am proud to help the company scale its technology and bring high-impact solutions to patients with neurological conditions and chronic pain.”

About Wise Spa and Enea Tech and Biomedical

WCS: wise cortical strip

YAOUNDE, Cameroon (AP) — Cameroon President Paul Biya on Thursday reached two months since the last time he was inside the borders of his country, a prolonged absence that has raised concerns for his health and criticisms about a possible power vacuum in the Central African nation.

The world’s oldest president, who has led Cameroon since 1982, began his eighth term in office in November after winning a widely disputed election in October. But the 93-year-old left the country on June 7 for what Biya's office described as “a brief private stay in Europe” that has become one of his longest trips overseas. His government later confirmed he was in Switzerland.

The health of the president has long been a topic of speculation as he spends significant time in Europe, including France and Switzerland, where he often spends weeks while leaving governance to key party officials and family members.

Cameroon’s constitution does not specifically prohibit a president from leaving the country for months. But without a vice president, an appointment Biya has full control over, the opposition has described the country as being run on “auto pilot.”

Opposition leader Issa Tchiroma Bakary, the presidential runner-up in October's election and a former Biya ally, said Thursday there is a widespread perception in Cameroon that “all is not well” with Biya, whose absence has angered the opposition.

“Biya’s very long stay in Switzerland only aggravates that lack of legitimacy and his desperate attempts to hold on to power by force,” Tchiroma said in a text message from exile in The Gambia.

The results of his nearly half-century in power have been mixed. Armed insurgencies by Boko Haram in the north and separatists in the west, along with a stagnant economy, have left many young people disillusioned with the leader.

Wilson Tamfuh, a professor of Public and International Law at the University of Dschang, compared Cameroon to a human body that is “seriously sick.”

“Even if Biya still proves to be strong at this age, it is clear that his health challenges are taking a toll on his leadership. Cabinet reshuffles over the past 15 years have amounted to little more than recycling the same people from one ministry to another,” Tamfuh said.

Biya's 2025 reelection sparked widespread protests that left at least four people dead, signaling significant tensions between the mostly young population and its aging leader.

On Monday, Biya reshuffled the top military leadership, replacing commanders of four of the country’s five joint military regions and promoting several senior officers to higher ranks. No official reason was given, but one of the replaced commanders had died and another retired.

Biya came to power following the resignation of Cameroon’s first president, Ahmadou Ahidjo, who served from 1960 to 1982.

A 2008 constitutional amendment abolished term limits, and Biya has now led Cameroon longer than most of its citizens have been alive: more than 70% of the country’s population of nearly 30 million people is below the age of 35.

If he serves his entire term, Biya will leave office at nearly 100 years old.

Wilson McMakin in Dakar, Senegal, contributed to this report.

FILE - Cameroon's President Paul Biya, of the Cameroon People's Democratic Movement party, waits to cast his vote during the presidential elections, Oct. 7, 2018, in Yaounde, Cameroon. (AP Photo/Sunday Alamba, File)